Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus TAZIDIME.
CEFACLOR vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 8 hours
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateCefaclor + Picosulfuric acid
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."